Trial Profile
A Phase II Study of Durvalumab (MEDI 4736) for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Jul 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Entecavir (Primary)
- Indications Hepatitis B; Liver cancer
- Focus Therapeutic Use
- 14 Jul 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.
- 14 Jul 2023 Planned primary completion date changed from 31 Dec 2023 to 31 Dec 2025.
- 12 Nov 2021 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.